Compare MVBF & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVBF | IPSC |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.1M | 370.2M |
| IPO Year | 2004 | 2021 |
| Metric | MVBF | IPSC |
|---|---|---|
| Price | $24.96 | $2.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $27.60 | $3.50 |
| AVG Volume (30 Days) | 26.6K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | 34.64 | ★ 91.30 |
| EPS | ★ 2.06 | N/A |
| Revenue | $3,400,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | $12.06 | ★ N/A |
| Revenue Growth | 51.92 | ★ 1556.76 |
| 52 Week Low | $15.59 | $0.34 |
| 52 Week High | $29.59 | $2.97 |
| Indicator | MVBF | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 46.07 |
| Support Level | $22.50 | $0.49 |
| Resistance Level | $25.00 | $2.68 |
| Average True Range (ATR) | 0.71 | 0.21 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 45.50 | 27.18 |
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.